What makes a cellular tissue product eligible for Section 361 regulation?

A product qualifies for Section 361 regulation under 21 CFR 1271 if it meets four core criteria: minimal manipulation, homologous use only, no combination with non-tissue drugs or devices, and lack of reliance on living cell metabolic activity (unless designated for autologous or specified reproductive use). If all four conditions are met, the tissue does not require premarket approval.

What is the primary difference between Section 361 and Section 351 HCT/Ps?

Section 361 products are regulated solely to prevent disease transmission and require minimal manipulation and homologous use without premarket approval. Section 351 products involve more-than-minimal manipulation or non-homologous use and are regulated as drugs, devices, or biological products requiring an Investigational New Drug (IND) application and premarket approval.

How should a practice document homologous use in patient records?

Practices should document the precise anatomical location of application, the structural function the tissue is providing (such as a barrier or cushion), and the clinical rationale matching original tissue function. Records should avoid using drug-like or systemic metabolic claims when documenting 361 tissue usage.

What records must a medical practice maintain for FDA HCT/P compliance?

Practices must maintain detailed tracking logs connecting donor tissue lot numbers to recipient patient charts, temperature monitoring logs for tissue storage units, Certificates of Analysis (COAs) for donor screening, and written standard operating procedures for adverse reaction reporting.

How can practice managers verify if a tissue vendor is FDA compliant?

Practice managers should request the supplier's active FDA Establishment Registration number (Form FDA 3488), review lot-specific Certificates of Analysis, inspect package insert claims for homologous intent, and verify that the manufacturer has not received FDA Warning Letters regarding 351 misclassification.

FDA Guidelines for 361 Human Cellular Tissue Products

FDA regulatory compliance guidelines for 361 human cellular tissue products require HCT/Ps to meet strict criteria for minimal manipulation, homologous use, and Current Good Tissue Practice (cGTP) under 21 CFR Part 1271. Clinical practices procurement teams sourcing biologics must independently verify supplier FDA Form 3356 registration, donor screening protocols, and promotional claims to mitigate operational liability. This operational guide details the specific verification steps medical directors and practice managers should implement when evaluating tissue product vendors.

Understanding the FDA 361 HCT/P Regulatory Framework

Under the Federal Food, Drug, and Cosmetic Act and the PHS Act, the Food and Drug Administration regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) through a risk-based tier system. Products categorized under Section 361 must satisfy four specific criteria defined in 21 CFR 1271.10(a):

Minimal Manipulation: The processing does not alter the original relevant characteristics of structural tissue (e.g., maintaining scaffolding properties) or the biological characteristics of non-structural tissue.
Homologous Use Only: The tissue is intended to perform the same basic function or functions in the recipient as in the donor.
No Combination with Other Articles: The product is not combined with another drug, device, or synthetic agent (except for specific permissible water, crystalloids, or sterilizing agents).
Metabolic Independence or Autologous Exception: The tissue does not rely on the metabolic activity of living cells for its primary function, OR if it does, it is designated for autologous use, first- or second-degree blood relatives, or reproductive use.

If an HCT/P fails any single criterion, it shifts from Section 361 status to Section 351, qualifying it as a biologic, drug, or medical device. Section 351 products require an Investigational New Drug (IND) application and premarket approval (BLA or PMA) before commercial distribution. Practices procuring high-quality biologics must ensure their clinical indications line up strictly with Section 361 definitions.

Clinical Considerations: Matching Tissues to Homologous Intent

For medical directors and treating clinicians, maintaining regulatory compliance hinges on how biological tissues are selected, described, and deployed in clinical practice. The FDA evaluates compliance based not only on manufacturer processing but also on marketing claims, clinical protocols, and promotional statements made by the clinical provider.

Structural Tissues vs. Metabolic Functions

Structural tissues—such as amnion, cord tissue, fascia, and adipose tissue—are intended to serve as protective barriers, mechanical cushions, or structural covers. When clinicians utilize structural allografts, clinical documentation must reflect structural intent rather than systemic regenerative or cellular metabolic claims. For example, using an amniotic membrane allograft as a protective wound barrier or cover is a recognized homologous use. Claiming that the same tissue cures systemic neurological conditions or acts via active living stem cells converts the product into an unapproved 351 drug in the eyes of regulatory inspectors.

Clinical Documentation Rigor

Clinicians in specialties such as pain management and orthopedic surgery must maintain clear treatment records:

Document the exact anatomical site of application and the structural objective of tissue placement.
Avoid describing treatments using non-compliant terminology (e.g., claiming "stem cell therapy" when applying acellular structural 361 tissues).
Ensure patient consent forms accurately state the biological classification and mechanical nature of the donor tissue.

Practice Management and Operational Compliance Checklist

Practice managers bear the operational responsibility of managing procurement, storage, inventory tracking, and adverse event logging. To safeguard the practice during regulatory audits, administrators should establish a standard operating procedure (SOP) based on the following compliance checklist:

FDA Registration Verification: Confirm that the tissue processor and supplier hold active registration on the FDA Establishment Registration system (Form FDA 3488).
Certificate of Analysis (COA) Archiving: Maintain lot-specific COAs for every tissue shipment, confirming donor screening for infectious diseases (HIV, Hepatitis B/C, Syphilis, HTLV).
Current Good Tissue Practice (cGTP) Documentation: Ensure the processor provides documentation demonstrating compliance with 21 CFR 1271 Subpart D.
Temperature Log Compliance: Maintain daily physical or digital temperature logs for cryopreservation units (-80°C freezers) or ambient storage spaces according to manufacturer instructions.
Traceability and Lot Tracking: Maintain a dual-entry log linking every tissue serial or lot number directly to the recipient patient record and the treating physician.
Adverse Reaction Reporting Procedure: Establish a written SOP for reporting adverse events or suspected tissue contamination to both the supplier and the FDA MedWatch system within required timelines.

Reviewing common operational protocols via our practice FAQ can help administrators standardize internal recordkeeping across clinical teams.

Risk Management and Vendor Audit Protocols

Vendor vetting is the single most critical line of defense for a medical practice utilizing biological products. Purchasing tissues from non-compliant entities exposes the practice to severe legal, financial, and regulatory liabilities.

When conducting vendor audits, administrators should request and evaluate the following documentation prior to issuing purchase orders:

FDA Form 483 and Warning Letter History: Ask tissue vendors to supply their compliance history and confirm whether they have received FDA 483 observations or Warning Letters regarding 351 vs. 361 misclassification.
Sterilization Validation Data: Confirm whether tissues undergo terminal sterilization (e.g., electron beam or gamma irradiation) or aseptic processing, and review validation summaries.
Labeling and Package Inserts: Verify that package inserts explicitly state structural applications and homologous use without unapproved biological claims.

Partnering with established medical distributors who adhere strictly to verified supply chains mitigates risk and ensures that all distributed products satisfy federal compliance standards. Learn more about our distribution standards on our about page.

What This Means for Your Practice: Concrete Next Steps

Translating FDA regulatory guidelines into daily practice management requires proactive administrative action:

Conduct an Internal Audit: Audit your current biologics inventory and promotional materials (website, brochures, patient consent forms) to eliminate non-homologous claims or improper terminology.
Update Standard Operating Procedures: Formulate clear SOPs covering receiving, storage, patient assignment, tissue tracking, and temperature monitoring.
Verify Supplier Credentials: Request updated FDA registration documents and lot-specific COAs from all current tissue vendors.
Train Clinical and Administrative Staff: Educate staff on the distinction between 361 HCT/Ps and 351 drugs to maintain consistent messaging and clinical compliance.

If your practice requires assistance evaluating compliance standards or procuring high-quality, fully compliant biological products, contact our team today for a dedicated operational consultation.